Clinical trial
Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With…
NCT00394745 · Novartis, Industry · Completed
Key facts
| NCT number | NCT00394745 |
|---|---|
| Title | Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome |
| Official title | A 12 Week Treatment, Open-label, Multicenter Study to Investigate the Efficacy and Safety of Valsartan 160-320 mg With Regard to Effects on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome |
| Lead sponsor | Novartis, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hypertension, Metabolic Syndrome |
| Intervention type | Drug |
| Interventions | Valsartan |
| Enrollment | 45 |
| Start date | Nov 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Nov 1, 2006 |
| Last update posted | Feb 24, 2017 |
| Countries | Germany, Switzerland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: